|52Wk High:||52Wk Low:|
CytRx Corp. is an oncology-focused research and development company with two molecules in clinical development. With its tumor-targeted conjugate aldoxorubicin, CytRx has initiated a phase 2b clinical trial for soft tissue sarcoma, has completed its phase 1b/2 trial and is preparing for a phase 3 clinical trial in second-line soft tissue sarcomas. CytRx has submitted a special protocol assessment for the phase 3 trial. Tamibarotene is being tested in a double-blind, placebo-controlled phase 2b trial in patients with non-small cell lung cancer. The company reached its enrollment target for that trial in February 2013.